BC Week In Review | Feb 22, 2019
Company News

SCM, Genexine purchase Argos

SCM Lifescience (Incheon, South Korea) and Genexine Inc. (KOSDAQ:095700) purchased all assets of Argos Therapeutics Inc. (Durham, N.C.) for $11.3 million and will rename the company CoImmune Inc. SCM will own 51% of CoImmune, while...
BC Week In Review | Jun 27, 2016
Company News

Adaptive Biotechnologies, Argos deal

The companies partnered to study immune responses induced by Argos’ AGS-003 and AGS-004 immunotherapies. Adaptive will use its immunoSEQ platform, a high throughput T and B cell receptor sequencing technology, to characterize immune profiles from...
BC Week In Review | Apr 20, 2015
Company News

Argos, Chongqing Lummy Pharmaceutical deal

Argos granted Chongquing Lummy’s Lummy Co. Ltd. subsidiary exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize AGS-003 for oncology indications. Argos is conducting the Phase III ADAPT study...
BC Extra | Apr 15, 2015
Company News

Lummy gains Chinese rights to Argos' AGS-003

Argos Therapeutics Inc. (NASDAQ:ARGS) granted the Lummy Co. Ltd. subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. (SZSE:300006) development and commercialization rights in greater China for AGS-003 in oncology indications. Argos is conducting a Phase III...
BC Week In Review | Jan 12, 2015
Clinical News

AGS-004: Phase IIb data

Top-line data from a double-blind, North American Phase IIb trial in 54 patients with chronic HIV-1 infection showed that AGS-004 missed the primary endpoint of a ³1.1 log reduction in viral load after the 12-week...
BC Extra | Jan 9, 2015
Clinical News

Argos falls on Phase IIb miss in HIV

Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy interruption...
BioCentury | Jun 24, 2013

Of cures & co-morbidities

The second meeting under FDA 's Patient-Focused Drug Development initiative has raised a conundrum for the agency and HIV companies. As the HIV population grows older and has more age-related co-morbidities, the need for drugs...
BioCentury | Mar 12, 2012

Argos plowing ahead

Argos Therapeutics Inc. is being coy about its financing plans after withdrawing its planned IPO on NASDAQ due to market conditions. But the company says it is going ahead next quarter with a $40-$50 million...
BC Extra | Mar 7, 2012
Financial News

Argos pulls IPO

Cancer immunotherapy company Argos Therapeutics Inc. (Durham, N.C.) withdrew its planned IPO citing market conditions. The company had planned to sell 5.3 million shares at $13-$15 per share. A $14 price would have raised $73.5...
BC Extra | Feb 17, 2012
Financial News

Argos sets IPO range

Argos Therapeutics Inc. (Durham, N.C.) amended its IPO and now plans to sell 5.3 million shares at $13-$15 per share. A $14 price would raise $73.5 million and value the company at $215.2 million. Lazard;...
Items per page:
1 - 10 of 24